Prime Medicine Inc (NASDAQ:PRME) shares, rose in value, without any change to the previous day’s close as strong demand from buyers drove the stock to $1.24.
Actively observing the price movement in the last trading, the stock closed the session at $1.24, falling within a range of $1.2137 and $1.2899. The value of beta (5-year monthly) was 1.887. Referring to stock’s 52-week performance, its high was $8.27, and the low was $1.12. On the whole, PRME has fluctuated by -38.00% over the past month.
With the market capitalization of Prime Medicine Inc currently standing at about $162.64 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-27.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PRME’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of PRME currently trading nearly -21.98% and -39.94% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 31.63, while the 7-day volatility ratio is showing 9.66% which for the 30-day chart, stands at 11.66%. Furthermore, Prime Medicine Inc (PRME)’s beta value is 2.15, and its average true range (ATR) is 0.18.
A comparison of Prime Medicine Inc (PRME) with its peers suggests the former has fared considerably weaker in the market. PRME showed an intraday change of 0.00% in last session, and over the past year, it shrunk by -76.47%%.
Data on historical trading for Prime Medicine Inc (NASDAQ:PRME) indicates that the trading volumes over the past 10 days have averaged 1.71 and over the past 3 months, they’ve averaged 1.31 million. According to company’s latest data on outstanding shares, there are 131.16 million shares outstanding.
Nearly 60.42% of Prime Medicine Inc’s shares belong to company insiders and institutional investors own 31.23% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 18.3 million shares as on 2025-03-31, resulting in a short ratio of 12.39. According to the data, the short interest in Prime Medicine Inc (PRME) stood at 2681.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 18.04 million. The stock has fallen by -57.53% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PRME stock heading into the next quarter.
